Ispinesib is primarily investigated for its potential in cancer treatment. It functions as a kinesin spindle protein (KSP) inhibitor, which plays a crucial role in cell division. By targeting KSP, Ispinesib disrupts the formation of the mitotic spindle, preventing cancer cells from dividing and proliferating. This mechanism makes it a promising candidate for therapies targeting various cancers, particularly those resistant to conventional treatments. Clinical trials have explored its efficacy in treating solid tumors and hematologic malignancies. Its ability to selectively target cancer cells while sparing normal cells offers a potential advantage in reducing side effects compared to traditional chemotherapy. Research continues to optimize its use, either as a standalone treatment or in combination with other anticancer agents.